



SEQUENCE LISTING

<110> Haruo Sugiyama

<120> CANCER ANTIGEN PEPTIDE FORMULATIONS

<130> 0020-5352PUS1

<140> US 10/527,692

<141> 2005-03-11

<150> PCT/JP2003/011675

<151> 2003-09-12

<160> 3

<210> 1

<211> 449

<212> PRT

<213> Homo sapiens

<400> 1

Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
1 5 10 15

Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
20 25 30

Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
35 40 45

Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro Pro
50 55 60

Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
65 70 75 80

Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
85 90 95

Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
100 105 110

Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
115 120 125

Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile
130 135 140

Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr
145 150 155 160

Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe
165 170 175

Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln

<220>

<223> Synthetic peptide derived from positions 235 to 243 of human WT1

<400> 2

Cys Met Thr Trp Asn Gln Met Asn Leu
1 5

<210> 3

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide of human WT1 wherein Met at position 236 in the
spanning region of positions 235 to 243 is altered into Tyr

<400> 3

Cys Tyr Thr Trp Asn Gln Met Asn Leu
1 5